Results 261 to 270 of about 116,176 (290)

Trisomy 8 in B-cell chronic lymphocytic leukemia

Cancer Genetics and Cytogenetics, 2008
Association between trisomy 8 and myeloid disorders/malignancies has been well documented. We report on two patients with a known history of B-cell chronic lymphocytic leukemia (B-CLL) with bone marrow involvement. In addition to the classic B-CLL cytogenetic abnormalities in one of the patients, both showed a trisomy 8 clone in their bone marrow ...
Olga, Pozdnyakova, Dariusz, Stachurski, Lloyd, Hutchinson, Sapna, Ramakrishnan, Patricia Minehart, Miron   +4 more
openaire   +2 more sources

Multidrug Resistance in B-Cell Chronic Lymphocytic Leukemia

Acta Haematologica, 1995
Multidrug resistance (MDR) was investigated in peripheral blood cells isolated from 40 patients with B cell chronic lymphocytic leukemia (B-CLL) and from 7 healthy volunteers, using a flow cytometric assay that detects cellular efflux of the fluorescent dye rhodamine 123 (Rh 123), which has been demonstrated to be transported from the cell by the P ...
I, Grulois, O, Fardel, B, Drenou, T, Lamy, P Y, Le Prisé, R, Fauchet   +5 more
openaire   +2 more sources

Targeting B Cell Signaling in Chronic Lymphocytic Leukemia

Current Oncology Reports, 2017
In recent years, a revolution in the management of chronic lymphocytic leukemia (CLL) has centered on the targeting of the B cell receptor (BCR) signaling pathway. Our improved understanding of the biology of cell signaling in CLL and the development of oral kinase inhibitors directed at the BCR pathway has led to the approval of two new agents and has
Jon E, Arnason, Jennifer R, Brown
openaire   +2 more sources

Alemtuzumab for B-cell chronic lymphocytic leukemia

Expert Review of Anticancer Therapy, 2008
Alemtuzumab (Campath, MabCampath) is a humanized therapeutic monoclonal antibody (mAb) that recognizes the CD52 antigen expressed on normal and neoplastic lymphoid cells. This mAb is active in previously treated patients with B-cell chronic lymphocytic leukemia (B-CLL) refractory to alkylating agents and purine nucleoside analogs.
openaire   +2 more sources

Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2008
A diagnosis of chronic lymphocytic leukemia (CLL) requires a count of over 5000 circulating CLL-phenotype cells per cubic millimeter. Asymptomatic persons with fewer CLL-phenotype cells have monoclonal B-cell lymphocytosis (MBL). The goal of this study was to investigate the relation between MBL and CLL.We investigated 1520 subjects who were 62 to 80 ...
Andy C, Rawstron, Fiona L, Bennett, Sheila J M, O'Connor, Marwan, Kwok, James A L, Fenton, Marieth, Plummer, Ruth, de Tute, Roger G, Owen, Stephen J, Richards, Andrew S, Jack, Peter, Hillmen   +10 more
openaire   +2 more sources

Stereotyped B-cell receptors in chronic lymphocytic leukemia

Leukemia & Lymphoma, 2014
Over the last decade, immunogenetic analysis of B-cell receptor immunoglobulins (BcR IGs) has proved to be a particularly fruitful field in chronic lymphocytic leukemia (CLL), not only for understanding disease pathogenesis but also for discriminating clinical subgroups with markedly distinct course and outcome.
Andreas, Agathangelidis, Anna, Vardi, Panagiotis, Baliakas, Kostas, Stamatopoulos   +3 more
openaire   +2 more sources

Genetic Features of B‐Cell Chronic Lymphocytic Leukemia

Reviews in Clinical and Experimental Hematology, 2000
The genetic features of B‐cell chronic lymphocytic leukemia CLL) are currently being reassessed by molecular cytogenetic techniques such as fluorescence in situ hybridization FISH). Conventional cytogenetic studies by chromosome banding are difficult in CLL mainly because of the low in vitro mitotic activity of the tumor cells, which leads to poor ...
S, Stilgenbauer, P, Lichter, H, Döhner
openaire   +2 more sources

Myelomonocytic antigens in B-cell chronic lymphocytic leukemia

Leukemia Research, 1995
The clinical significance of myelomonocytic (MyMo) antigens in B-cell chronic lymphocytic leukemia (B-CLL) is unclear. We have analyzed the expression of MyMo antigens (CD13, CD14 (LeuM3, My4, Mo2), CD15, CD11b, CD11c, CD33 and CD68) on B-lymphocytes (CD19+) in 105 B-CLL patients and in 35 controls.
D, Tàssies, E, Montserrat, J C, Reverter, N, Villamor, M, Rovira, C, Rozman   +5 more
openaire   +2 more sources

p53 Mutations in B-Cell Chronic Lymphocytic Leukemia

1992
The p53 gene is a nuclear phosphoprotein that can function as a tumor suppressor gene (Michalovitz et al. 1991). Frequent mutations of the p53 gene have been detected in several types of solid tumors including breast (Mackay et al. 1988), colon (Vogelstein et al. 1989), lung (Yokota et al. 1987), liver carcinoma (Hsu et al. 1991), astrocytoma (Fults et
S, el Rouby, W, Bayona, S M, Pisharody, E W, Newcomb   +3 more
openaire   +2 more sources

B-cell receptor signaling in chronic lymphocytic leukemia

Blood, 2011
AbstractThe B-cell receptor (BCR) is a key survival molecule for normal B cells and for most B-cell malignancies. Recombinatorial and mutational patterns in the clonal immunoglobulin (Ig) of chronic lymphocytic leukemia (CLL) have revealed 2 major IgMD-expressing subsets and an isotype-switched variant, each developing from distinct B-cell populations.
Stevenson, FK, Krysov, S, Davies, AJ, Steele, AJ, Packham, G   +4 more
openaire   +3 more sources